Literature DB >> 7340888

Relationship between the transplacental gradients of bupivacaine and alpha 1-acid glycoprotein.

M C Petersen, R G Moore, R L Nation, W McMeniman.   

Abstract

1 The binding of bupivacaine (400 ng/ml) to isolated alpha 1-acid glycoprotein was studied at two protein concentrations. At 20 mg/100 ml the extent of bupivacaine binding was 31.0 +/- 1.8% (mean +/- s.d., n = 4), and at a protein concentration of 60 mg/100 ml binding of bupivacaine was 85.8 +/- 1.5% (n = 4). 2 Bupivacaine and alpha 1-acid glycoprotein concentrations were measured in plasma samples collected from a maternal peripheral vein and the umbilical vein at delivery (n = 23). The ratio of the foetal:maternal bupivacaine concentrations ranged from 0.17 to 0.52, while the foetal:maternal ration for alpha 1-acid glycoprotein concentrations ranged from 0.20 to 0.96. A positive relationship emerged between the two ratios (P less than 0.01). 3 The alpha 1-acid glycoprotein concentration gradient across the placenta, and interindividual variability in the gradient appear to contribute to the low and variable transplacental bupivacaine concentration ratio observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7340888      PMCID: PMC1401940          DOI: 10.1111/j.1365-2125.1981.tb01321.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Plasma protein binding and placental transfer of bupivacaine.

Authors:  J Thomas; G Long; G Moore; D Morgan
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

2.  Bupivacaine binding to plasma protein fractions.

Authors:  L E Mather; J Thomas
Journal:  J Pharm Pharmacol       Date:  1978-10       Impact factor: 3.765

3.  Seromucoid and albumin levels in maternal and cord serum in relation to obstetric stress.

Authors:  W Good; T E Cochran; H N Macdonald; K N Cumberbatch
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-08

4.  The binding of bupivacaine to maternal and foetal plasma proteins.

Authors:  L E Mather; G J Long; J Thomas
Journal:  J Pharm Pharmacol       Date:  1971-05       Impact factor: 3.765

5.  The maternal plasma levels and placental transfer of bupivacaine following epidural analgesia.

Authors:  J Thomas; C R Climie; L E Mather
Journal:  Br J Anaesth       Date:  1969-12       Impact factor: 9.166

6.  Orosomucoid and alpha 1-antitrypsin in maternal and fetal sera at parturition.

Authors:  C B Laurell
Journal:  Scand J Clin Lab Invest       Date:  1968       Impact factor: 1.713

7.  Binding of anilide-type local anesthetics in human plasma. II. Implications in vivo, with special reference to transplacental distribution.

Authors:  G T Tucker; R N Boyes; P O Bridenbaugh; D C Moore
Journal:  Anesthesiology       Date:  1970-09       Impact factor: 7.892

Review 8.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 9.  Drug kinetics in childbirth.

Authors:  R L Nation
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

10.  Bupivacaine 0.125% in epidural block analgesia during childbirth: maternal and foetal plasma concentrations.

Authors:  K Geerinckx; G Vanderick; A L Van Steenberge; R Bouche; E De Muylder
Journal:  Br J Anaesth       Date:  1974-12       Impact factor: 9.166

View more
  9 in total

Review 1.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

2.  Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus-infected pregnant women.

Authors:  Rodrigo Metzker Pereira Ribeiro; Fernanda de Lima Moreira; Elaine Christine Dantas Moisés; Ricardo Carvalho Cavalli; Silvana Maria Quintana; Vera Lucia Lanchote; Geraldo Duarte
Journal:  Br J Clin Pharmacol       Date:  2018-08-02       Impact factor: 4.335

Review 3.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Protein binding of the analgesics alfentanil and sufentanil in maternal and neonatal plasma.

Authors:  W Meuldermans; R Woestenborghs; H Noorduin; F Camu; A van Steenberge; J Heykants
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state.

Authors:  M D Hill; F P Abramson
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

Review 6.  Plasma protein binding of drugs in pregnancy.

Authors:  E Perucca; A Crema
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

7.  Disposition of betamethasone in parturient women after intravenous administration.

Authors:  M C Petersen; C B Collier; J J Ashley; W G McBride; R L Nation
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of fentanyl and its newer derivatives.

Authors:  L E Mather
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 9.  Models for placental transfer studies of drugs.

Authors:  P Bourget; C Roulot; H Fernandez
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.